Trailing Twelve Months Revenue Growth: ProPhase Labs, Inc. (PRPH)

Scaling B2B contracts for genomic sequencing and oncology diagnostics is forcing ProPhase Labs, Inc. (PRPH) to strictly control costs following the decline in pandemic-related revenues. Annual sales volume growth over the trailing four quarters is available for analysis on GURU.Markets, where the parameter value reaches 0.00. This confirms the status of a dynamic player whose consumer trust is based on the accuracy of rapid tests and the quality of health products.

For ProPhase Labs, Inc. (PRPH), the pace of revenue expansion reflects the effective synergy between the laboratory diagnostics and dietary supplement segments. This metric is calculated as the percentage change in total trailing 12-month revenues compared to the previous year. By analyzing the annual sales dynamics over four quarters, an investor can discern the actual speed of business scaling. This growth confirms the success of diversifying sales markets; however, accelerating profits do not eliminate the risk of share price overvaluation.